• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5107272)   Today's Articles (2810)
For: Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martin A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Alia EMG, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023:S0923-7534(23)00686-5. [PMID: 37211045 DOI: 10.1016/j.annonc.2023.05.005] [Citation(s) in RCA: 132] [Impact Index Per Article: 66.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 05/05/2023] [Accepted: 05/10/2023] [Indexed: 05/23/2023]  Open
Number Cited by Other Article(s)
1
Mukherjee UA, Miller RE, Ledermann JA. Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer. Ther Adv Med Oncol 2025;17:17588359251343973. [PMID: 40529205 PMCID: PMC12171271 DOI: 10.1177/17588359251343973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2025] [Accepted: 05/06/2025] [Indexed: 06/20/2025]  Open
2
Denisenko TV, Ivanova AE, Koval A, Silachev DN, Jia L, Sukhikh GT, Katanaev VL. Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers. Mol Syst Biol 2025:10.1038/s44320-025-00125-1. [PMID: 40490498 DOI: 10.1038/s44320-025-00125-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2025] [Revised: 05/08/2025] [Accepted: 05/20/2025] [Indexed: 06/11/2025]  Open
3
Zheng Z, Wang H, Yang H, Tang J, Cheng X, Zhang M, Ren Y, Chen X, Ju X, Xu L, Wu X. Efficacy of Maintenance Therapy With Adjuvant Chemotherapy of Three Steps in Patients Newly Diagnosed With Advanced Ovarian Cancer: A Phase II Randomised Clinical Trial. BJOG 2025;132 Suppl 4:52-61. [PMID: 40292604 DOI: 10.1111/1471-0528.18178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2024] [Accepted: 04/08/2025] [Indexed: 04/30/2025]
4
Shao Z, Wen Q, Chen X, Hong J, Yu W, Zhou H, Zhu Y, Zhu T. Clinical Practice of Poly (ADP-Ribose) Polymerase Inhibitors for Maintenance Treatment of Platinum-Sensitive Recurrent Ovarian Cancer in China. BJOG 2025;132 Suppl 4:13-19. [PMID: 40313193 DOI: 10.1111/1471-0528.18182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2024] [Accepted: 04/08/2025] [Indexed: 05/03/2025]
5
Monk BJ, Lorusso D, Fujiwara K, Sehouli J. Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review. Cancer Treat Rev 2025;137:102945. [PMID: 40349571 DOI: 10.1016/j.ctrv.2025.102945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2025] [Revised: 04/17/2025] [Accepted: 04/18/2025] [Indexed: 05/14/2025]
6
Lara Gutierrez A, Halbwedl I, Sauer S, Regitnig P, Petru E, Seeböck R, Schubert S, Peternell C, Bodó K, Prein K, Kashofer K. Robust Assessment of Homologous Recombination Deficiency Genomic Instability by OncoScan Microarrays. J Mol Diagn 2025;27:475-484. [PMID: 40188947 PMCID: PMC12163384 DOI: 10.1016/j.jmoldx.2025.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2024] [Revised: 01/08/2025] [Accepted: 02/28/2025] [Indexed: 04/13/2025]  Open
7
Xie L, Lin S, Liu Y, Ling X, Lin Z. The Forefront of Maintenance Therapy for Newly Diagnosed Advanced Ovarian Cancer in China: A Review of Updated Evidence With PARP Inhibitors. BJOG 2025;132 Suppl 4:5-12. [PMID: 40259471 DOI: 10.1111/1471-0528.18180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2024] [Accepted: 04/08/2025] [Indexed: 04/23/2025]
8
Moore KN, Liu JF, Lorusso D. State of the Art: Therapies Now and Around the Corner for Gynecologic Cancers. Am Soc Clin Oncol Educ Book 2025;45:e473114. [PMID: 40489723 DOI: 10.1200/edbk-25-473114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2025]
9
Endo Y, Takagawa Y, Yoshimoto Y, Machida M, Dai Y, Azami Y, Seto I, Takayama K, Suzuki M, Nakasato T, Kikuchi Y, Kato T, Yamaguchi A, Soeda S, Fujimori K, Murakami M. Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer: a single-center retrospective study. J Ovarian Res 2025;18:110. [PMID: 40426272 PMCID: PMC12108022 DOI: 10.1186/s13048-025-01695-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2024] [Accepted: 05/14/2025] [Indexed: 05/29/2025]  Open
10
Marconato N, Tommasi OD, Paladin D, Boscarino D, Spagnol G, Saccardi C, Maggino T, Tozzi R, Noventa M, Marchetti M. Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing Platforms. Cancers (Basel) 2025;17:1771. [PMID: 40507252 PMCID: PMC12153926 DOI: 10.3390/cancers17111771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2025] [Revised: 05/22/2025] [Accepted: 05/23/2025] [Indexed: 06/16/2025]  Open
11
Amer H, Flanagan KL, Kampan NC, Itsiopoulos C, Scott CL, Kartikasari AER, Plebanski M. Interleukin-6 Is a Crucial Factor in Shaping the Inflammatory Tumor Microenvironment in Ovarian Cancer and Determining Its Hot or Cold Nature with Diagnostic and Prognostic Utilities. Cancers (Basel) 2025;17:1691. [PMID: 40427188 PMCID: PMC12109964 DOI: 10.3390/cancers17101691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2025] [Revised: 05/05/2025] [Accepted: 05/09/2025] [Indexed: 05/29/2025]  Open
12
Feng H, Zhao LY, Xu Z, Xie QF, Deng HJ, Yu J, Liu H. Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China. World J Gastrointest Oncol 2025;17:102767. [DOI: 10.4251/wjgo.v17.i5.102767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2024] [Revised: 02/14/2025] [Accepted: 03/07/2025] [Indexed: 05/15/2025]  Open
13
Evans E, Dholakia J, Abraham J, Hinton A, Zhang J, Xiu J, Maney T, Oberley M, Thacker P, Herzog TJ, Spetzler D, Arend RC. Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors. Gynecol Oncol 2025;197:139-145. [PMID: 40344964 DOI: 10.1016/j.ygyno.2025.04.586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2025] [Revised: 04/17/2025] [Accepted: 04/24/2025] [Indexed: 05/11/2025]
14
Apelian S, Martincuks A, Whittum M, Yasukawa M, Nguy L, Mathyk B, Andikyan V, Anderson ML, Rutherford T, Cristea M, Stewart D, Kohut A. PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies. Biomedicines 2025;13:1126. [PMID: 40426953 PMCID: PMC12108591 DOI: 10.3390/biomedicines13051126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2025] [Revised: 04/24/2025] [Accepted: 04/29/2025] [Indexed: 05/29/2025]  Open
15
Coleman RL, Segunmaru Z, Szamreta EA, Krupsky K, Beusterien K, Cambron-Mellott MJ, Barry MF, Kashine N, Mulvihill E, Simmons D. Oncologist perceptions of "cure" and long-term management in advanced ovarian cancer in the United States: results from a cross-sectional survey. Int J Gynecol Cancer 2025;35:101919. [PMID: 40398290 DOI: 10.1016/j.ijgc.2025.101919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2025] [Revised: 04/21/2025] [Accepted: 04/27/2025] [Indexed: 05/23/2025]  Open
16
Ethier JL, Shephard C, Granados DP, Dutta N, Qadeer R, Ahmad S, Kasireddy E, Pourrahmat MM, Fazeli MS. Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison. Gynecol Oncol 2025;196:1-9. [PMID: 40132433 DOI: 10.1016/j.ygyno.2025.03.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2024] [Revised: 02/18/2025] [Accepted: 03/12/2025] [Indexed: 03/27/2025]
17
Pignata S, Oza A, Hall G, Pardo B, Madry R, Cibula D, Klat J, Montes A, Glasspool R, Colombo N, Pete I, Herrero Ibáñez A, Romeo M, Ilieva R, Timcheva C, Di Maio M, Bashir Z, Taylor R, Barnicle A, Clamp A. Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status. Br J Cancer 2025;132:725-732. [PMID: 40097725 PMCID: PMC11997082 DOI: 10.1038/s41416-025-02966-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2024] [Revised: 01/27/2025] [Accepted: 02/19/2025] [Indexed: 03/19/2025]  Open
18
Said SA, IntHout J, Koffijberg H, de Hullu JA, Hyde SE, van der Aa MA, van Altena AM. External validation of prediction models for early relapse in advanced epithelial ovarian cancer using Australian and Dutch population-based data. Cancer Epidemiol 2025;97:102824. [PMID: 40315577 DOI: 10.1016/j.canep.2025.102824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2024] [Revised: 04/10/2025] [Accepted: 04/11/2025] [Indexed: 05/04/2025]
19
Habaka M, Daly GR, Shinyanbola D, Alabdulrahman M, McGrath J, Dowling GP, Hehir C, Huang HYR, Hill ADK, Varešlija D, Young LS. PARP Inhibitors in the Neoadjuvant Setting; A Comprehensive Overview of the Rationale for their Use, Past and Ongoing Clinical Trials. Curr Oncol Rep 2025;27:533-551. [PMID: 40192976 DOI: 10.1007/s11912-025-01669-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/11/2025] [Indexed: 05/16/2025]
20
Kulkarni S, Seneviratne N, Tosun Ç, Madhusudan S. PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapy. DNA Repair (Amst) 2025;149:103830. [PMID: 40203475 DOI: 10.1016/j.dnarep.2025.103830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2024] [Revised: 03/20/2025] [Accepted: 03/26/2025] [Indexed: 04/11/2025]
21
Chinczewski L, Harter P, Heukamp L, Mayr D, Grimm C, Heinzelmann-Schwarz V, Wimberger P, Mahner S, Braicu IE, Schmitt W, Denkert C, Sehouli J. Intergroup-statement: statement of the german ovarian cancer commission, the North-Eastern German Society of gynecological Oncology (NOGGO), AGO Austria and AGO Swiss regarding the use of homologous repair deficiency (HRD) assays in advanced ovarian cancer. Arch Gynecol Obstet 2025;311:1445-1450. [PMID: 40069521 PMCID: PMC12033106 DOI: 10.1007/s00404-025-07991-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2025] [Accepted: 02/21/2025] [Indexed: 04/29/2025]
22
Xiao H, Cheng G, Zhang H, Liu Y, Chen Z, Gao Y, Gao F, Liu Y, Wang S, Kong B. Role of KLF5 in enhancing ovarian cancer stemness and PARPi resistance: mechanisms and therapeutic targeting. J Transl Med 2025;23:492. [PMID: 40307891 PMCID: PMC12042437 DOI: 10.1186/s12967-025-06502-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2024] [Accepted: 04/13/2025] [Indexed: 05/02/2025]  Open
23
Micha JP, Rettenmaier MA, Bohart R, Gorman JP, Goldstein BH. Clinical differences among the PARP inhibitors in the first-line treatment of advanced-stage ovarian carcinoma. Expert Rev Anticancer Ther 2025:1-5. [PMID: 40249727 DOI: 10.1080/14737140.2025.2496519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2025] [Revised: 04/03/2025] [Accepted: 04/17/2025] [Indexed: 04/20/2025]
24
Kordowitzki P, Lange B, Elias KM, Haigis MC, Mechsner S, Braicu IE, Sehouli J. Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer. CA Cancer J Clin 2025. [PMID: 40252048 DOI: 10.3322/caac.70008] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2025] [Revised: 02/20/2025] [Accepted: 02/26/2025] [Indexed: 04/21/2025]  Open
25
Geissler F, Graf F, Zwimpfer TA, Eller RS, Nguyen-Sträuli BD, Schötzau A, Heinzelmann-Schwarz V, Gobrecht-Keller U. Endocrine Maintenance Therapy in High-Grade Serous Ovarian Cancer: A Retrospective Off-Label Real-World Cohort Study. Cancers (Basel) 2025;17:1301. [PMID: 40282477 PMCID: PMC12025638 DOI: 10.3390/cancers17081301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2025] [Revised: 04/06/2025] [Accepted: 04/10/2025] [Indexed: 04/29/2025]  Open
26
Ergasti R, Vertechy L, Ruscito I, Boccia SM, Congedo L, Sassu CM, Capomacchia FM, Costantini B, Distefano MG, Scambia G, Fagotti A, Marchetti C. Failure of early interval debulking surgery after standard neoadjuvant chemotherapy: May bevacizumab add something? A large retrospective study. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 2025;51:110016. [PMID: 40209282 DOI: 10.1016/j.ejso.2025.110016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2025] [Revised: 03/19/2025] [Accepted: 04/03/2025] [Indexed: 04/12/2025]
27
Xu H, George E, Gallo D, Medvedev S, Wang X, Datta A, Kryczka R, Hyer ML, Fourtounis J, Stocco R, Aguado-Fraile E, Petrone A, Yin SY, Shiwram A, Liu F, Anderson M, Kim H, Greenberg RA, Marshall CG, Simpkins F. Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Nat Commun 2025;16:3112. [PMID: 40169546 PMCID: PMC11962063 DOI: 10.1038/s41467-025-58183-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Accepted: 03/14/2025] [Indexed: 04/03/2025]  Open
28
Kataoka N, Hata T, Hosomi K, Hirata A, Fujiwara S, Goto E, Nishihara M, Ohmichi M, Neo M. Predictors of olaparib discontinuation owing to adverse drug events in patients with ovarian, peritoneal, or fallopian tube cancer: a retrospective observational study. J Chemother 2025;37:168-174. [PMID: 38695665 DOI: 10.1080/1120009x.2024.2345025] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 03/20/2024] [Accepted: 04/15/2024] [Indexed: 03/09/2025]
29
Karacin P. Ovarian carcinoma in patients aged ≥80 years: A retrospective multicenter study of management and survival in the FRANCOGYN population: letter to the editor. J Gynecol Obstet Hum Reprod 2025;54:102919. [PMID: 39892517 DOI: 10.1016/j.jogoh.2025.102919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2025] [Accepted: 01/29/2025] [Indexed: 02/03/2025]
30
Stanisławiak-Rudowicz J, Szałek E, Więckowska B, Grześkowiak E, Mądry R. Olaparib-induced hyperglycemia in ovarian cancer patients - a case series analysis of a three-month therapy with a consideration of BMI. Pharmacol Rep 2025;77:500-507. [PMID: 39881056 DOI: 10.1007/s43440-025-00702-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2024] [Revised: 01/14/2025] [Accepted: 01/16/2025] [Indexed: 01/31/2025]
31
Galeș LN, Păun MA, Butnariu I, Simion L, Manolescu LSC, Trifănescu OG, Anghel RM. Next-Generation Sequencing in Oncology-A Guiding Compass for Targeted Therapy and Emerging Applications. Int J Mol Sci 2025;26:3123. [PMID: 40243903 PMCID: PMC11988731 DOI: 10.3390/ijms26073123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2025] [Revised: 03/17/2025] [Accepted: 03/21/2025] [Indexed: 04/18/2025]  Open
32
Chitoran E, Rotaru V, Stefan DC, Gullo G, Simion L. Blocking Tumoral Angiogenesis VEGF/VEGFR Pathway: Bevacizumab-20 Years of Therapeutic Success and Controversy. Cancers (Basel) 2025;17:1126. [PMID: 40227654 PMCID: PMC11988089 DOI: 10.3390/cancers17071126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2025] [Revised: 03/22/2025] [Accepted: 03/26/2025] [Indexed: 04/15/2025]  Open
33
Kang B, Lee SJ, Seol KH, Jeong YY, Choi JH, Choi BH, Ryu JM, Choi YS. Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib. Int J Mol Sci 2025;26:2921. [PMID: 40243501 PMCID: PMC11989182 DOI: 10.3390/ijms26072921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2025] [Revised: 03/06/2025] [Accepted: 03/17/2025] [Indexed: 04/18/2025]  Open
34
Kong B, Zheng W. Mirvetuximab soravtansine: current and future applications. J Hematol Oncol 2025;18:33. [PMID: 40102896 PMCID: PMC11921575 DOI: 10.1186/s13045-025-01686-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2025] [Accepted: 03/07/2025] [Indexed: 03/20/2025]  Open
35
Wang YW, Allen I, Funingana G, Tischkowitz M, Joko-Fru YW. Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review. BJC REPORTS 2025;3:14. [PMID: 40069561 PMCID: PMC11897386 DOI: 10.1038/s44276-025-00122-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/01/2024] [Revised: 12/06/2024] [Accepted: 01/09/2025] [Indexed: 03/15/2025]
36
Zhang K, Qiu Y, Feng S, Yin H, Liu Q, Zhu Y, Cui H, Wei X, Wang G, Wang X, Shen Y. Development of model for identifying homologous recombination deficiency (HRD) status of ovarian cancer with deep learning on whole slide images. J Transl Med 2025;23:267. [PMID: 40038690 PMCID: PMC11877705 DOI: 10.1186/s12967-025-06234-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2024] [Accepted: 02/11/2025] [Indexed: 03/06/2025]  Open
37
Moser SC, Jonkers J. Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers. Cancer Discov 2025;15:461-480. [PMID: 40025950 PMCID: PMC11893084 DOI: 10.1158/2159-8290.cd-24-1326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2024] [Revised: 11/04/2024] [Accepted: 12/06/2024] [Indexed: 03/04/2025]
38
Muzzana M, Broggini M, Damia G. The Landscape of PARP Inhibitors in Solid Cancers. Onco Targets Ther 2025;18:297-317. [PMID: 40051775 PMCID: PMC11884256 DOI: 10.2147/ott.s499226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2024] [Accepted: 02/05/2025] [Indexed: 03/09/2025]  Open
39
Uccella S, Puppo A, Garzon S, Palladino S, Zorzato PC, Leone Roberti Maggiore U, Zavallone L, Calandra V, Galli L, Franchi M, Raspagliesi F. Secondary cytoreductive surgery for ovarian cancer recurrence and first-line maintenance therapy: A multicenter retrospective study. Eur J Obstet Gynecol Reprod Biol 2025;306:160-167. [PMID: 39988402 DOI: 10.1016/j.ejogrb.2025.01.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2024] [Revised: 01/11/2025] [Accepted: 01/14/2025] [Indexed: 02/25/2025]
40
Asare A, Previs RA, Spinosa D, Fellman B, Scott AL, Mulder I, Mahmoud M, Enbaya A, Siedel JH, Cobb L, Soliman PT, Sood AK, Coleman RL, Secord AA, Westin SN. Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression. Gynecol Oncol 2025;194:112-118. [PMID: 39987772 PMCID: PMC12115928 DOI: 10.1016/j.ygyno.2025.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2024] [Revised: 02/16/2025] [Accepted: 02/17/2025] [Indexed: 02/25/2025]
41
Dinkins KG, Lee GM, Arend RC, Leath CA, Toboni MD. Trends in FDA approvals of gynecologic oncology therapeutics from 2019 to 2024. Gynecol Oncol 2025;194:153-158. [PMID: 40221174 DOI: 10.1016/j.ygyno.2025.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2024] [Revised: 03/05/2025] [Accepted: 03/06/2025] [Indexed: 04/14/2025]
42
Motohashi T, Shimada M, Tokunaga H, Kuwahara Y, Kuwabara H, Kato A, Tabata T. Niraparib as maintenance therapy in Japan: a retrospective observational study using a Japanese claims database. J Gynecol Oncol 2025;36:e19. [PMID: 39028152 PMCID: PMC11964971 DOI: 10.3802/jgo.2025.36.e19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2024] [Revised: 06/06/2024] [Accepted: 06/25/2024] [Indexed: 07/20/2024]  Open
43
Chattaraj A, Mishra V, Mishra Y. Carbon Nanotubes in the Diagnosis and Treatment of Ovarian Cancer. Indian J Microbiol 2025;65:538-553. [PMID: 40371046 PMCID: PMC12069779 DOI: 10.1007/s12088-024-01367-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 07/28/2024] [Indexed: 05/16/2025]  Open
44
Hage Chehade C, Gebrael G, Sayegh N, Ozay ZI, Narang A, Crispino T, Golan T, Litton JK, Swami U, Moore KN, Agarwal N. A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin 2025;75:141-167. [PMID: 39791278 PMCID: PMC11929130 DOI: 10.3322/caac.21870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2024] [Accepted: 10/03/2024] [Indexed: 01/12/2025]  Open
45
Farolfi A, Montanari D, Casadei C, Musolino A. Perspectives, Challenges, and Advances in Therapeutic Strategies for Gynecological Malignant Tumors. Biomedicines 2025;13:528. [PMID: 40002940 PMCID: PMC11853204 DOI: 10.3390/biomedicines13020528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2025] [Revised: 01/14/2025] [Accepted: 02/10/2025] [Indexed: 02/27/2025]  Open
46
Marmé F, Krieghoff-Henning EI, Kiehl L, Wies C, Hauke J, Hahnen E, Harter P, Schouten PC, Brodkorb T, Kayali M, Heitz F, Zamagni C, González-Martin A, Treilleux I, Kommoss S, Prieske K, Gaiser T, Fröhling S, Ray-Coquard I, Pujade-Lauraine E, Brinker TJ. Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides. Eur J Cancer 2025;216:115199. [PMID: 39742559 DOI: 10.1016/j.ejca.2024.115199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2024] [Accepted: 12/21/2024] [Indexed: 01/03/2025]
47
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2025;36:185-196. [PMID: 39528049 DOI: 10.1016/j.annonc.2024.10.828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2024] [Revised: 10/30/2024] [Accepted: 10/31/2024] [Indexed: 11/16/2024]  Open
48
Hunt A, Ditri D, Chadha A, Keogh G, Thompson J, Loughborough W, McNeish I, Krell J, McDermott J, Tookman L, Ghaem-Maghami S. Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success. Future Oncol 2025;21:341-347. [PMID: 39611711 PMCID: PMC11792859 DOI: 10.1080/14796694.2024.2433412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2024] [Accepted: 11/20/2024] [Indexed: 11/30/2024]  Open
49
Bogani G, Moore KN, Ray-Coquard I, Lorusso D, Matulonis UA, Ledermann JA, González-Martín A, Kurtz JE, Pujade-Lauraine E, Scambia G, Caruso G, Raspagliesi F, Colombo N, Monk BJ. Incorporating immune checkpoint inhibitors in epithelial ovarian cancer. Gynecol Oncol 2025;193:30-40. [PMID: 39764856 DOI: 10.1016/j.ygyno.2024.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2024] [Revised: 11/08/2024] [Accepted: 12/18/2024] [Indexed: 03/03/2025]
50
Shi Y, Zhu S, Shan J, Xu Y. Disease-free survival of 15 years after primary surgery in a patient with advanced high-grade serous ovarian cancer: a case report and literature review. Front Oncol 2025;15:1468196. [PMID: 39931084 PMCID: PMC11807797 DOI: 10.3389/fonc.2025.1468196] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2024] [Accepted: 01/06/2025] [Indexed: 02/13/2025]  Open
PrevPage 1 of 3 123Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA